TearLab Corp (TEAR) was Upgraded by Feltl & Co. to ” Strong Buy”. Earlier the firm had a rating of “Buy ” on the company shares. Feltl & Co. advised their investors in a research report released on May 5, 2016.
On the company’s financial health, TearLab Corp reported $-0.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 4, 2016. Analyst had a consensus of $-0.23. The company had revenue of $6.80 million for the quarter, compared to analysts expectations of $6.82 million. The company’s revenue was up 25.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.25 EPS.
TearLab Corp opened for trading at $0.74 and hit $0.8501 on the upside on Wednesday, eventually ending the session at $0.8202, with a gain of 8.48% or 0.0641 points. The heightened volatility saw the trading volume jump to 8,83,741 shares. Company has a market cap of $28 M.
TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company is engaged in commercial manufacturing of the TearLab Osmolarity System. The Company’s wholly owned subsidiary TearLab Research Inc. develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries metabolites (glucose) genes and proteins) at the point-of-care. The TearLab Osmolarity System measures tear film osmolarity for the diagnosis of Dry Eye Disease (DED). The TearLab Osmolarity System is an integrated testing system consisted of: the TearLab disposable the TearLab Pen and the TearLab Reader.